CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1 enrolled
Drug / intervention
ATI-50002drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03551821
NCT03551821Phase 2Completed
CompareCT.gov

An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Aclaris Therapeutics, Inc.·interventional·Posted Jun 11, 2018·Updated Dec 11, 2019

In Brief

A Phase 2 clinical trial evaluating ATI-50002 for Alopecia Areata and 2 related conditions. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution in subjects with unilateral or bilateral loss of eyebrow hair due to alopecia areata (AA), alopecia universalis (AU) or alopecia totalis (AT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata, Alopecia Totalis, Alopecia Universalis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 11, 2018
Enrollment StartApr 11, 2018
Primary CompletionNov 6, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.1 years ago

Interventions

ATI-50002drug

Topical Solution